Scarica l'app Stockscreener
131.14
1.57%
2.03
Dopo l'orario di chiusura:
131.44
0.30
+0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$129.11
Aprire:
$129.13
Volume 24 ore:
8.55M
Relative Volume:
1.24
Capitalizzazione di mercato:
$162.70B
Reddito:
$29.05B
Utile/perdita netta:
$8.11B
Rapporto P/E:
20.31
EPS:
6.4563
Flusso di cassa netto:
$9.16B
1 W Prestazione:
+8.15%
1M Prestazione:
+5.62%
6M Prestazione:
+19.03%
1 anno Prestazione:
+40.95%
Intervallo 1D:
$129.00
$133.10
Intervallo di 1 settimana:
$122.10
$133.10
Portata 52W:
$92.21
$133.10
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
131.14 | 160.18B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,087.38 | 965.30B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.49 | 525.25B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
218.11 | 382.02B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
145.00 | 278.44B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.23 | 263.59B | 46.69B | 15.29B | 9.25B | 3.4329 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Why Gilead Sciences (GILD) Outpaced the Stock Market Today - Yahoo Finance
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer - GlobeNewswire Inc.
Gilead Sciences publishes Trodelvy-Keytruda data in NEJM - The Pharma Letter
Cell Therapy Market Dynamics and Contributions by Gilead - openPR.com
Gilead Sciences Inc. (NASDAQ:GILD) Passes the Caviar Cruise Quality Investing Screen - Chartmill
Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
GILD: Gilead Sciences Reports Positive Results for Trodelvy and Keytruda Combo - GuruFocus
Gilead Sciences (NASDAQ:GILD) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Gilead Sciences stock hits all-time high at 128.71 USD By Investing.com - Investing.com Nigeria
Gilead Sciences stock hits all-time high at 128.71 USD - Investing.com
Rothschild & Co Redburn Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences (GILD) Valuation Check After Recent Share Price Softness - Yahoo Finance New Zealand
Universal Beteiligungs und Servicegesellschaft mbH Lowers Position in Gilead Sciences, Inc. $GILD - MarketBeat
Migdal Insurance & Financial Holdings Ltd. Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
US Stocks Recap: What is the PEG ratio of Gilead Sciences IncPrice Action & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced (NASDAQ:GILD) - Seeking Alpha
The Truth About Gilead Sciences Inc: Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Bernstein reiterates Outperform rating on Gilead stock with $135 price target - Investing.com
Gilead Sciences, Inc. $GILD Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Royal Bank Of Canada Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
40 Under 40: Calvin Yan Ting Chan, Gilead Sciences - Medical Marketing and Media
Stocks Generating Improved Relative Strength: Gilead Sciences - Investor's Business Daily
Gilead Sciences Earnings Outlook: Key Points to Watch - Bitget
Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF GILEAD SCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Gilead Sciences Earnings Preview: What to Expect - Barchart.com
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Allstate Corp Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Nasdaq Futures Spotlight Biopharma Scale - Kalkine Media
Csenge Advisory Group Has $2.38 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Campbell & CO Investment Adviser LLC Invests $1.40 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by QRG Capital Management Inc. - MarketBeat
HER2-Negative Metastatic Breast Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai - Barchart.com
Insider Sell: Andrew Dickinson Sells 3,000 Shares of Gilead Scie - GuruFocus
Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares of Stock - MarketBeat
Gilead Sciences CCO Mercier sells $372,930 in stock - Investing.com
Gilead Sciences CFO Dickinson sells $372,930 in stock - Investing.com India
The Truth About Gilead Sciences: Is This ‘Boring’ Pharma Stock About To Blow Up? - AD HOC NEWS
Hedge Fund Moves: Whats the analyst consensus on Gilead Sciences IncWeekly Profit Recap & Fast Gain Stock Tips - baoquankhu1.vn
Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade) (NASDAQ:GILD) - Seeking Alpha
Looking Into Gilead Sciences Inc's Recent Short Interest - Benzinga
Gilead Sciences, Inc. $GILD Shares Purchased by Ritholtz Wealth Management - MarketBeat
GILD Stock Price, Forecast & Analysis | GILEAD SCIENCES INC (NASDAQ:GILD) - Chartmill
Short Covering: Is GCTSWS stock a good pick for beginnersJuly 2025 Chart Watch & Expert Approved Trade Ideas - baoquankhu1.vn
Gilead stock holds Buy rating at UBS as Yeztugo launch shows promise - Investing.com
Gilead Sciences, Inc. $GILD Shares Sold by Conning Inc. - MarketBeat
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes - BioSpace
Gilead Sciences, Inc. (GILD) Stock Analysis: Strong Buy Ratings and 10.84% Potential Upside - DirectorsTalk Interviews
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Manning & Napier Advisors LLC Has $13.65 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences CFO Andrew Dickinson sells $14 million in stock - MSN
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.81%
1.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):